2023
Allograft tissue under the microscope: only the beginning
Virmani S, Rao A, Menon M. Allograft tissue under the microscope: only the beginning. Current Opinion In Organ Transplantation 2023, 28: 126-132. PMID: 36787238, PMCID: PMC10214011, DOI: 10.1097/mot.0000000000001052.Peer-Reviewed Original ResearchConceptsAllograft tissueArtificial intelligenceBanff schemaMachine learningDigital pathologyKidney allograft biopsiesApplication of AINovel molecular diagnosticsAllograft healthAllograft histologyAllograft biopsiesPathologic diagnosisImmunological activationTissue injuryHistopathological analysisClinical careTissue pathologyML algorithmsClinical useOrdinal outputsNovel modalityVivo microscopyPathologyBiopsyTissue
2022
Update on Renal Sympathetic Denervation for the Treatment of Hypertension
Rao A, Krishnan N. Update on Renal Sympathetic Denervation for the Treatment of Hypertension. Current Cardiology Reports 2022, 24: 1261-1271. PMID: 35895182, DOI: 10.1007/s11886-022-01753-x.Peer-Reviewed Original ResearchConceptsRenal sympathetic denervationTreatment of hypertensionRenal sympathetic nervesPathophysiology of hypertensionSympathetic denervationSympathetic nervesBlood pressureSafety of RSDRenal sympathetic nerve fibersAmbulatory blood pressure measurementsAntihypertensive drug useSham-controlled trialAdvanced kidney diseaseSympathetic nerve fibersLong-term efficacyPurpose of ReviewHypertensionBlood pressure measurementsExcellent safety profileModest treatment effectsLong-term safetyAntihypertensive medicationsAldosterone antagonistsCause mortalityNeurogenic controlResistant hypertensionDonor–Recipient Non-HLA Variants, Mismatches and Renal Allograft Outcomes: Evolving Paradigms
Jethwani P, Rao A, Bow L, Menon MC. Donor–Recipient Non-HLA Variants, Mismatches and Renal Allograft Outcomes: Evolving Paradigms. Frontiers In Immunology 2022, 13: 822353. PMID: 35432337, PMCID: PMC9012490, DOI: 10.3389/fimmu.2022.822353.Peer-Reviewed Original ResearchConceptsAllograft outcomesImportant recent dataRenal allograft outcomeAcute allograft rejectionKidney allograft outcomesDonor-recipient mismatchRecipient's immune systemNatural history studiesNon-HLA lociMajority of casesOrgan allocation processPolymorphic HLA genesAcute rejectionAllograft longevityAllograft lossMaintenance immunosuppressionTransplant outcomesAllograft rejectionImmune mechanismsPatient deathRecipient pairsDonor organsHLA variantsImmune systemOvert evidence
2020
Talaromycosis in a Patient on Nintedanib for Interstitial Lung Disease
Madgula A, Covello B, Singh M, Rao A, Lee J. Talaromycosis in a Patient on Nintedanib for Interstitial Lung Disease. Cureus 2020, 12: e7215. PMID: 32274273, PMCID: PMC7141794, DOI: 10.7759/cureus.7215.Peer-Reviewed Original ResearchInterstitial lung diseaseLung diseaseTreatment of interstitial lung diseaseAdvent of immunotherapyAcquired immunodeficiency syndromeTyrosine kinase inhibitorsGrowth factor receptorSmall-sized studiesShortness of breathFibroblast growth factor receptorImmunodeficiency syndromeClinical presentationDormant infectionTalaromycosisFactor receptorFungal infectionsKinase inhibitorsRespiratory symptomsTreat several conditionsEndemic regionsNintedanibPatientsInfectionDiseaseImmunotherapyLife-threatening hypertriglyceridemia-induced pancreatitis related to alectinib successfully treated by plasmapheresis: A review of the literature on metabolic toxicities associated with anaplastic lymphoma kinase inhibitors
Rao A, Reddy A, Dinunno C, Elali I. Life-threatening hypertriglyceridemia-induced pancreatitis related to alectinib successfully treated by plasmapheresis: A review of the literature on metabolic toxicities associated with anaplastic lymphoma kinase inhibitors. Journal Of Oncology Pharmacy Practice 2020, 26: 1533-1537. PMID: 32054410, DOI: 10.1177/1078155220904141.Peer-Reviewed Original ResearchConceptsAnaplastic lymphoma kinase inhibitorsTriglyceride levelsAcute pancreatitisKinase inhibitorsMetastatic non-small cell lung cancerNon-small cell lung cancerHypertriglyceridemia-induced acute pancreatitisAnaplastic lymphoma kinase (ALK) rearrangementAnaplastic lymphoma kinase (ALK) mutationsAggressive multidisciplinary managementHypertriglyceridemia-induced pancreatitisPatient's triglyceride levelStage IIIA adenocarcinomaCommon adverse effectsTraditional risk factorsCell lung cancerRight hilar massStandard of careTyrosine kinase inhibitorsEpigastric painConcurrent chemoradiationIntravenous hydrationRespiratory failureRight hilumElevated triglyceridesSuccessful treatment of Hashimoto encephalopathy with therapeutic plasma exchange
bin Attique H, Rao A, Haider L, Trivedi R. Successful treatment of Hashimoto encephalopathy with therapeutic plasma exchange. Therapeutic Apheresis And Dialysis 2020, 24: 599-601. PMID: 31863616, DOI: 10.1111/1744-9987.13466.Peer-Reviewed Original Research